Dartmouth College

Dartmouth Digital Commons
Dartmouth Scholarship

Faculty Work

8-31-2009

Distinction of the Memory B Cell Response to Cognate Antigen
Versus Bystander Inflammatory Signals
Micah J. Benson
Dartmouth College

Raul Elgueta
Dartmouth College

William Schpero
Dartmouth College

Michael Molloy
Dartmouth College

Weijun Zhang
Dartmouth College

See next page for additional authors

Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Medicine and Health Sciences Commons

Dartmouth Digital Commons Citation
Benson, Micah J.; Elgueta, Raul; Schpero, William; Molloy, Michael; Zhang, Weijun; Usherwood, Edward;
and Noelle, Randolph J., "Distinction of the Memory B Cell Response to Cognate Antigen Versus
Bystander Inflammatory Signals" (2009). Dartmouth Scholarship. 2649.
https://digitalcommons.dartmouth.edu/facoa/2649

This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has
been accepted for inclusion in Dartmouth Scholarship by an authorized administrator of Dartmouth Digital
Commons. For more information, please contact dartmouthdigitalcommons@groups.dartmouth.edu.

Authors
Micah J. Benson, Raul Elgueta, William Schpero, Michael Molloy, Weijun Zhang, Edward Usherwood, and
Randolph J. Noelle

This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/2649

ARTICLE

Distinction of the memory B cell response
to cognate antigen versus bystander
inflammatory signals
Micah J. Benson, Raul Elgueta, William Schpero, Michael Molloy,
Weijun Zhang, Edward Usherwood, and Randolph J. Noelle

The Journal of Experimental Medicine

Department of Microbiology and Immunology, Dartmouth Medical School and the Norris Cotton Cancer Center,
Lebanon, NH 03756

The hypothesis that bystander inflammatory signals promote memory B cell (BMEM) selfrenewal and differentiation in an antigen-independent manner is critically evaluated
herein. To comprehensively address this hypothesis, a detailed analysis is presented examining the response profiles of B-2 lineage B220+IgG+ BMEM toward cognate protein antigen in
comparison to bystander inflammatory signals. After in vivo antigen encounter, quiescent
BMEM clonally expand. Surprisingly, proliferating BMEM do not acquire germinal center (GC)
B cell markers before generating daughter BMEM and differentiating into plasma cells or
form structurally identifiable GCs. In striking contrast to cognate antigen, inflammatory
stimuli, including Toll-like receptor agonists or bystander T cell activation, fail to induce
even low levels of BMEM proliferation or differentiation in vivo. Under the extreme conditions of adjuvanted protein vaccination or acute viral infection, no detectable bystander
proliferation or differentiation of BMEM occurred. The absence of a BMEM response to nonspecific inflammatory signals clearly shows that BMEM proliferation and differentiation is a
process tightly controlled by the availability of cognate antigen.
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Abbreviations used: ASC, antibody-secreting cell; BCR, B
cell receptor; BMEM, memory B
cell; GC, germinal center; IF,
immunofluorescence; KLH,
keyhole limpet hemocyanin;
MZ, marginal zone; NF, naive
follicular; NP, 4-hydroxy-3nitrophenylacetyl; PB, plasmablast; PC, plasma cell; PE,
phycoerythrin; SHM, somatically hypermutated; sPE, soluble
PE; TLR, Toll-like receptor;
VACVWR, vaccinia virus Western reserve strain.

Life-long immunity is central to the survival of
the host. This immunity is engendered by the
persistence of memory T cells, memory B cells
(BMEM), and long-lived BM plasma cells (PCs;
Amanna et al., 2007; Dörner and Radbruch,
2007). Long-lasting B cell–mediated immunity
has been referred to as serological memory
(Traggiai et al., 2003) and can be sustained by
recurrent antigen exposure. In the absence of
periodic exposure to antigen, it is thought that
the production of inflammatory signals to un
related antigens serve as mediators sustaining serologic memory through activation of BMEM in
a noncognate manner. The in vitro and in vivo
response profiles of antigen-specific BMEM to
cognate antigen and “nonspecific” or bystander
inflammatory mediators are analyzed herein to
critically evaluate the mechanisms underlying
the maintenance of serological memory.
BMEM and long-lived PCs are the products
of the germinal center (GC) reaction and express somatically hypermutated (SHM) immuno
globulin receptors of the switched isotypes
(MacLennan, 1994; McHeyzer-Williams and
Ahmed, 1999). After BMEM exit from the GC
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reaction, they colonize the splenic marginal
zones (MZs) and the B cell follicles, where they
reside in a quiescent state for months or, likely,
years (Liu et al., 1988, 1991; Schittek and
Rajewsky, 1990; Anderson et al., 2007). Upon
rechallenge with cognate antigen, histological
studies in rats observed that BMEM egress toward the T cell–rich periarteriolar lymphocytic
sheath and, upon receiving T cell help, proliferate and differentiate into plasmablasts (PBs)
situated in both the periarteriolar lymphocytic
sheath and in the splenic red pulp (Liu et al.,
1991). Kinetic studies indicate that the generation of this response is rapid and peaks 4-5 d
after secondary antigen encounter (Liu et al.,
1991; McHeyzer-Williams et al., 2000; Minges
Wols et al., 2007). The PB response dissipates
shortly after its initiation, with a subset of PBs
further differentiating into long-lived PCs resident in the BM (Liu et al., 1991; Manz et al.,
© 2009 Benson et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months
after the publication date (see http://www.jem.org/misc/terms.shtml). After six
months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons
.org/licenses/by-nc-sa/3.0/).
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1997; McHeyzer-Williams et al., 2006). Shortly after recall, BMEM cells are once again present in their initial anatomical positions (Liu et al., 1991). Despite numerous
studies carefully mapping out the events of the primary
humoral immune response toward protein antigens (Jacob
et al., 1991; MacLennan, 1994; Allen et al., 2007), relatively little is known about the events occurring during a
secondary humoral immune response, including whether
antigen reencounter results in the expression of GC markers by antigen-responding BMEM and/or if BMEM form GC
structures en route to differentiating into PCs (Liu et al.,
1991; MacLennan, 1994; McHeyzer-Williams et al., 2006).
As the fate and behavior of antigen-activated BMEM is critical to our understanding of BMEM self-renewal, included in
this study is a detailed analysis of the in vivo response of
BMEM toward cognate antigen.
The mechanisms mediating the survival of BMEM are unknown. Although BMEM require phospholipase C  signaling
through the B cell receptor (BCR) for survival, it is clear that
the BMEM BCR need not be permanently engaged with antigen, as BMEM do not require the presence of persisting antigen or antigen complexes to survive (Maruyama et al., 2000;
Anderson et al., 2006; Hikida et al., 2009). It is apparent that
BMEM occupy a survival niche independent from other B-2
lineage cell subsets, as, unlike all other mature cells of the B-2
lineage, they do not require BAFF and APRIL survival signals (Benson et al., 2008; Scholz et al., 2008). At the level of
the organism, it is thought that humoral memory as a whole
is sustained by the stem cell–like qualities of BMEM, with this
cell type undergoing low levels of self-renewal and replenishment of the long-lived PC pool over the lifetime of the organism (Traggiai et al., 2003). To sustain serological memory
in the absence of cognate antigen, it has been hypothesized
that quiescent BMEM are periodically activated by Toll-like
receptor (TLR) agonists or bystander T cell help to undergo
self-renewal events and differentiate into antibody-secreting
cells (ASCs) such as PBs and PCs in an antigen-independent
manner (Bernasconi et al., 2002). A crucial element of this
theory was the prediction that inflammatory stimuli associated with adaptive immune responses drive the activation of
BMEM in an antigen-independent (i.e., nonspecific) manner
in vivo (Bernasconi et al., 2002, 2003; Traggiai et al., 2003).
Whether BMEM are indeed reactive to bystander inflammatory stimuli in vivo has not yet been tested from the vantage
point of BMEM.
In this work, we detail the ability of BMEM to undergo
self-renewal and to differentiate into ASCs in response to
both antigen-dependent and bystander inflammatory stimuli.
In studying these events, we also demonstrate that during
clonal expansion in response to cognate antigen, BMEM do
not express a GC B cell phenotype, and that GC structures
are not generated en route to differentiating into ASCs. We
find that BMEM are responsive to inflammatory stimuli in vitro, with activated BMEM displaying a markedly enhanced capacity to differentiate into ASCs when compared with naive
follicular (NF) B cells. However, in vivo, in response to TLR
2014

agonists, polyclonal T cell activation, protein vaccination,
and even acute vaccinia virus infection, BMEM neither clonally expand nor differentiate into ASCs, and thus appear ignorant to overt bystander inflammatory signals.
RESULTS
Antigen-specific and polyclonal BMEM cells are responsive
to TLR agonists in vitro and display an enhanced capacity
to differentiate into ASCs when compared with NF B cells
A comprehensive analysis of BMEM responsiveness to antigen
and bystander inflammatory stimuli was undertaken both in
vitro and in vivo. The term “bystander” is defined herein as
stimuli acting on BMEM independent of BCR engagement.
In these studies, we tracked BMEM specific for the thymusdependent protein antigen R-phycoerythrin (PE), as immunization of BALB/c mice with this fluorophore elicits a
detectable population of PE-binding BMEM at a high resolution (referred to as PE-BMEM; Hayakawa et al., 1987). After
immunization with PE adsorbed to alum i.p., PE-BMEM are
readily detectable in the spleen at 0.01–0.05% of total splenocytes beginning 21 d after immunization, with this population still present 60 d after priming (Fig. S1; Hayakawa et al.,
1987; Schittek and Rajewsky, 1990; Benson et al., 2008). In
nonimmunized mice, a minute naive PE-binding population
is observed at a 10-fold lower frequency (Fig. S1). The PEBMEM in immunized mice are predominantly B220+PE+CD3
8+IgDIgG1+CD80hi and express a phenotype consistent
with long-lived affinity-matured BMEM (Fig. S1; Anderson
et al., 2007). In all experiments (unless indicated otherwise),
PE-BMEM from PE/alum-immunized mice were analyzed
between days 60 and 90 after primary immunization.
The response of PE-BMEM to inflammatory stimuli was
first analyzed by examining the response profile of BMEM to a
panel of TLR agonists in vitro. We also included two other
sources of BMEM in these in vitro analyses to first ensure that
the results were reproducible in multiple systems and to test
whether BMEM activation occurs in the absence of BCR
cross-linking. The second system used BMEM raised against
and specific for the hapten 4-hydroxy-3-nitrophenylacetyl
(NP), with this system having been previously characterized
(McHeyzer-Williams et al., 1991; Lalor et al., 1992). The
third system used BMEM from a transgenic mouse in which
the polyclonal BMEM population is readily identified. This latter source allowed for the isolation of BMEM without the need
for BCR engagement by antigen, as when PE-BMEM and
NP-BMEM are purified using antigen binding to denote specificity, cross-linking the BCR is inevitable.

PE-BMEM cells. From PE-immunized mice, PE-BMEM
were first enriched by negative selection, and then electronically sorted based on a B220+PE+dumpCD38+ phenotype, with post-sort analysis indicating high levels of
purity (Fig. S2 A).
NP-specific BMEM cells. NP-BMEM were generated in a
transgenic mouse strain where Cre recombinase was inserted
IN VIVO ACTIVATION OF MEMORY B CELLS | Benson et al.
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in the C1 locus, with this strain crossed with the Rosa26EYFP reporter mouse (Casola et al., 2006). In this mouse,
every post-GC B cell expresses YFP, with this strain affording the opportunity to track post-GC B cell subsets by YFP
expression (Casola et al., 2006). Immunization of C1-cre/
Rosa26-EYFP mice with NP-keyhole limpet hemocyanin
(KLH)/alum lead to the generation of NP-BMEM (Fig. S2 B;
Casola et al., 2006). After negative enrichment, NP-BMEM
were defined as B220+ NIP+IgG1/YFP+dumpCD38+, with
post-sort analysis indicating purity (Fig. S2 B).
Polyclonal BMEM cells. Polyclonal BMEM can be clearly
enumerated in C1-cre/Rosa26-EYFP mice through expression of YFP, loss of IgD and IgM, and expression of other
BMEM markers. NP-immunized C1-cre/Rosa26-EYFP
mice were negatively enriched for BMEM with polyclonal
BMEM defined as B220+IgG1/YFP+CD38+dumpCD80+
and sorted to purity (Fig. 1 C).
NF B cells. In parallel, NF B cells were defined as
B220+CD23+IgD+CD38+ and were additionally sorted
(Fig. S2 C).
The response of PE-BMEM, NP-BMEM, poly-BMEM, and
NF B cells to TLR agonists after 3 d of in vitro culture was
analyzed (Fig. 1). PE-BMEM and corresponding NF B cells
and IL-4–only controls were stained with CFSE, whereas
NP-BMEM and poly-BMEM with NF B cells and IL-4 only
controls were stained with DDAO to track proliferation. After culture with the TLR4 agonist LPS, cells were analyzed
for surface expression of B220 and CD138. The culture of
all NF and BMEM with IL-4 resulted in a uniform B220+ population after 3 d (unpublished data). Upon culture of NF B
cells and BMEM with LPS, NF B cells remained primarily
B220+CD138, whereas all three sources of BMEM generated
a B220intCD138+ population of cells (21–30% of total) representing the phenotype of a ASC (Fig. 1, A and D). The
ASCs derived from the three sources of BMEM were of the
IgG isotype and, with the ASCs generated from PE-BMEM
and NP-BMEM, specific for either PE or NP, respectively
(Fig. 1 G and not depicted). NF B cells generated a high frequency of IgM+ ASCs (Fig. 1 G). The overall degree of proliferation by the three sources of BMEM was moderately less
than NF B cells, although proliferation did occur, as indicated by comparison to the IL-4–only cultured cells (Fig. 1,
B and E). The population of B220intCD138+ cells generated
from poly-BMEM arose in the daughter peaks, showing that
BMEM undergo cell division while differentiating into
B220intCD138+ cells (Fig. 1 F).
The response of poly-BMEM and NF B cells was analyzed
to either Pam3CSK4 (TLR1/2 agonist), heat-killed Listeria
monocytogenes (TLR2 agonist), poly(I:C) (TLR3 agonist),
LPS (TLR4 agonist), flagellin from Salmonella typhimurium
(TLR5 agonist), FSL-1 (TLR6 agonist), S-27609 (TLR7 agonist), ODN 1826 (TLR9 agonist), and IL-4. Both NF B
cells and poly-BMEM were responsive to agonists for TLR1/2,
TLR4, TLR6, TLR7, and TLR9 (Fig. 1 I). Both poly-BMEM
JEM VOL. 206, August 31, 2009

and NF B responded poorly or did not respond to agonists
for TLR2, TLR3, and TLR5 (unpublished data). For each
TLR agonist that NF B cells or poly-BMEM responded to,
BMEM generated a sizable population of B220intCD138+ cells,
whereas NF B cells maintained a B220+CD138 phenotype
(Fig. 1 H). NF B cells also proliferated to a greater degree
than BMEM (Fig. 1 I). Finally, it was observed that while engagement of CD40 drove proliferation of both BMEM and NF
B cells, BMEM did not differentiate into B220intCD138+ cells
(Fig. 1, H–I). Collectively, these data show that BMEM are
sensitive to multiple TLR agonists in vitro and do not require BCR cross-linking to become activated and differentiate into ASCs. Furthermore, upon activation, BMEM have an
enhanced intrinsic capacity to differentiate into CD138+
ASCs compared with NF B cells. Lastly, CD40 signaling appears to drive BMEM proliferation, but to block differentiation
in vitro.
BMEM cells undergo rapid clonal expansion
and differentiation into IgG+ ASCs in response
to soluble antigen
Having established that BMEM are responsive to bystander
stimuli in vitro, we used the PE-antigen system to compare
BMEM responsiveness toward cognate antigen versus bystander
inflammation in vivo. We first performed a detailed analysis
of the secondary humoral immune response to soluble PE
(sPE) to define the behavior and kinetics of BMEM activation
in vivo. Unlike naive hosts, it is well-established that previously immunized mice are responsive to low-doses of antigen
in the absence of adjuvant (McHeyzer-Williams et al., 2006).
This heightened responsiveness results from the combined
presence of antigen-reactive BMEM and CD4+ memory T
cells. In concordance with this, we observed that injection of
naive mice with 1 µg sPE (or 10 µg; not depicted) failed to
elicit PE-ASCs (Fig. 2, A and B), whereas PE-immunized
mice produced high numbers of IgG+ PE-ASCs. A robust
IgM ASC response was only elicited when naive or PE-immunized mice were injected with 1 µg of sPE along with the
TLR9 agonist CpG ODN 1826 (CpG; Fig. 2 A). Thus, the
IgG+ PE-specific humoral response generated after sPE injection is likely the direct consequence of BMEM activation.
These data demonstrate that a low level of sPE given in the
absence of adjuvant is capable of activating PE-BMEM to differentiate into IgG+ ASCs.
The in vivo proliferation of PE-BMEM was measured by
flow cytofluorimetric analysis of BrdU incorporation. PEimmunized mice were injected with sPE, and a 5-d BrdU pulse
was performed starting on the day of sPE injection, followed
by a chase period. BrdU incorporation by BMEM was quantified
at various times during and after the pulse period. After preenrichment, PE-BMEM were detected by excluding CD4/CD8/
IgD/IgM+ cells via a dump gate and gating them on B220+PE+
cells, with these cells analyzed for BrdU incorporation (Fig. S3 A).
PE-immunized mice receiving BrdU, but no antigen, and
immunized mice receiving neither antigen nor BrdU were
included as negative controls (Fig. 2 C). 2 d after sPE
2015

Figure 1. Antigen-specific and polyclonal BMEM cells are responsive to TLR agonists in vitro and display an enhanced capacity to differentiate into ASCs compared with NF B cells. NP-BMEM and PE-BMEM were sorted by FACS, along with NF B cells. NP-BMEM and NF B cells were stained with
DDAO and PE-BMEM, and NF B cells were stained with CFSE. Cells were cultured for 3 d with 10 µg/ml LPS, whereupon the cell surface phenotype was
analyzed for the expression of B220 and CD138 (A) or DDAO or CFSE (B), with the percentage of B220+CD138+ cells depicted (A). (B) Filled histograms,
B cells + IL-4; gray lines, BMEM; black lines, NF B cells. To analyze the reactivity of BMEM to TLR agonists in the absence of BCR cross-linking, poly-BMEM were
used. Spleens from NP-KLH–immunized C1-cre/ROSA-YFP mice were enriched for BMEM, with poly-BMEM present in the remaining population sorted by
the phenotype B220+IgG1/YFP+CD38+DumpCD80+. Dump gates, CD43+IgD+IgM+ cells (C). Both poly-BMEM and NF B cells were labeled with DDAO and
cultured for 3 d in the presence of either 10 µg/ml LPS or 5 µM CpG, whereupon the cell surface phenotype was analyzed for the expression of B220 and
CD138 (D) and DDAO dye dilution (E). (E) Gray lines, B cells + IL-4; black lines, NF or poly-BMEM as indicated. Proliferation as a function of CD138 expression is shown, with the percentage of cells that have diluted DDAO and are expressing CD138 shown (F). The ability of cells derived from either NF B cells
(open bars) or BMEM (filled bars) after 3 d of LPS culture to secrete antibody of the IgM, IgG1, IgG2a, IgG2b, IgG3, IgE, and IgA isotypes was analyzed by
ELISpot analysis (F). The response profiles of poly-BMEM and NF B cells to a panel of TLR agonists was examined after 3 d of culture with the indicated
agonist. The agonists used, their abbreviations, the receptors for which they are specific for, and the concentrations used are as follows: Pam3CSK4 (P3C),
TLR1/2, 1 µg/ml; LPS (LPS), TLR4, 10 µg/ml; FSL-1 (FSL1), TLR6/2, 1 µg/ml; S-27609 (609), TLR7, 1 µg/ml; CpG ODN 1826 (CpG), TLR9, 5 µM, CD40
2016
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rechallenge, BMEM began to proliferate, with this response
peaking by day 4 (Fig. 2 C and Fig. S3 A). In mice analyzed
during the BrdU chase period (days 11 and 24 after sPE rechallenge), a proportion of BMEM remained BrdU+ at a percentage
similar to that observed at the peak of the response (35.5% ±
SEM 4.6 and 38.4% ± SEM 5.1 versus 48.9% ± SEM 5.8, respectively), indicating that 71–77% of BMEM proliferation occurs within the first 5 d after antigen rechallenge (Fig. 2 C and
Fig. S3 A). A second PE-binding population was also observed
in these experiments, with this population displaying a
B220PE+ phenotype (Fig. S3 A). When the BrdU incorporation frequencies by the B220PE+ population in PBS versus
sPE-immunized mice were compared, no differences were
observed between the two groups over the 24-d kinetic
analysis (unpublished data). This indicates that the B220PE+
population does not respond to sPE, and as antigen-responsiveness is a crucial element of adaptive memory, we excluded
these cells from further analysis. As BrdU labeling measures
the accumulation of proliferation over the time of the BrdU
“pulse” period, we also analyzed BMEM expression of Ki-67 at
various times after antigen challenge (Fig. 2 F). Ki-67 expression is an indicator of all stages of the cell cycle and provides a
snapshot of the proliferative state of the BMEM at a given point
in time (Gerdes et al., 1984). PE-BMEM are almost uniformly
Ki-67, which is indicative of their quiescent state (Fig. 2 F).
By days 3 and 4 after sPE rechallenge, 76–77% of BMEM cells
were Ki-67+. At day 5, Ki-67 expression began to dissipate,
and most PE-BMEM exhibited decreased Ki-67 expression on
day 7, with this decrease more pronounced by day 11. By day
24, PE-BMEM were once again uniform in their lack of Ki-67
expression (Fig. 2 F). In correlating the expression pattern of
Ki-67 by BMEM (Fig. 2 F) with the 5-d BrdU pulse followed by
a chase period (Fig. 2 C), the results indicate that the majority
of BMEM proliferation occurs between days 2 and 5 after sPE
rechallenge. In addition, the presence of BrdU+ BMEM 24 d after sPE injection provides direct evidence that BMEM generate
daughter BMEM after secondary antigen encounter.
A rapid increase in the numbers of IgG+ PE-ASCs in
both the spleen and BM was observed 3 d after sPE rechallenge (Fig. 2, B and D). This burst in ASC numbers peaked
4 d after challenge in the spleen and 5 d in the BM, after
which ASC numbers gradually subsided over the next 20 d
(Fig. 2 D). Corresponding to the increase of ASCs after rechallenge was an increase in anti-PE IgG serum titers increasing 10-fold over the next 20 d (Fig. 2 E). These data show
that ASCs are rapidly generated within 3 d after antigen rechallenge and are present to substantial degrees in both the
spleen and the BM. Soon thereafter, ASC numbers declined,
indicating that short-lived ASCs are present in both organs.

The observation that 50% of BMEM respond to sPE as
indicated by BrdU incorporation (Fig. 2 C and Fig. S3 A) led
us to question whether either the antigen dose or the absence
of adjuvant during antigen administration was limiting the
frequency of responding BMEM. To test this, we varied the
amount of sPE injected or added CpG during antigen rechallenge, with BrdU administration concurrently initiated.
When analyzed 3 d later, it was observed that the dose of antigen positively correlated with the percentage of proliferating BMEM (Fig. 2 G and Fig. S3 B). The addition of CpG had
no further impact on the frequency of responding PE-BMEM
(Fig. 2 G and Fig. S3 C). However, the addition of CpG to
sPE modestly increased the number of splenic IgG+ PE-ASCs
elicited after 3 d when compared with sPE alone (Fig. 2 B).
In sum, these data indicate that antigen can be a limiting factor in dictating the frequency of responding BMEM. Notably,
TLR9 agonists failed to enhance the frequency of activated
BMEM. This point indicates that CpGs alone may not play a
role in driving in vivo BMEM activation.
BMEM cells proliferate upon in vivo antigen encounter
and do not express GC markers or generate GC structures
The rapid kinetics of the BMEM response led us to question
whether BMEM form GCs after antigen encounter. Clonally
expanding BMEM were tracked to define their transitional
stages en route to differentiating into ASCs. Under steadystate conditions, PE-BMEM displayed a GL7PNAKi67CD38+ phenotype as anticipated (Fig. 3 A; Lalor et al.,
1992). As a positive control for GC markers, Peyer’s patches
were harvested and gated on B220+IgD cells, a population
known to be primarily GC B cells, with these cells exhibiting
a GL7+PNA+Ki-67hiCD38 phenotype (Butcher et al.,
1982). When PE-BMEM were harvested and analyzed 3 d after
sPE challenge, they were GL7PNAKi-67hiCD38+, indicating these cells had responded to antigen because of Ki-67
expression, yet failed to express the GC markers GL7 and
PNA (Fig. 3 A). It was plausible that the failure of antigenresponding BMEM to gain a GC phenotype was caused by the
solitary use of sPE, and that the induction of a GC phenotype
requires the presence of an adjuvant. Therefore, CpG was
added to sPE, and 3 d later, the phenotype of the responding
BMEM was analyzed. The addition of CpG to sPE again elicited GL7PNAKi-67hiCD38+ BMEM (Fig. 3 A). It was considered possible that BMEM gain a GC phenotype later than 3 d
after antigen encounter, so the phenotype of BMEM was analyzed at later points in time. The results indicate that PE-BMEM
maintain a GL7PNACD38+ phenotype throughout the
cell cycle (Fig. 3 B). These data define a proliferating state
of BMEM occurring shortly after in vivo antigen encounter,

(CD40), CD40, 10 µg/ml; and IL-4, 10 ng/ml. The percentage of B220intCD138+ cells derived from NF B cells (open bars) or BMEM (filled bars; H) and the
percentage of cells proliferating as measured by dye dilution of DDAO (I) are depicted. Data presented is representative (A–G) or pooled (H and I) from
three to five independent experiments. Purified BMEM are pooled from six to eight mice per experiment, with NF B cells isolated from one mouse per experiment. Results in G–I are expressed as the mean ± SEM.
JEM VOL. 206, August 31, 2009
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Figure 2. BMEM cells undergo rapid self-renewal and differentiation into IgG+ PCs in response to soluble antigen. Either naive or PE-immunized
mice were challenged with PBS, 1 µg sPE, or 1 µg sPE + 50 µg CpG and 3 d later, IgM+, and IgG+ PE-PCs from the spleen were quantified by ELISPOT
(A and B). To measure the proliferation of BMEM, PE-immunized mice were injected with 5 µg sPE or PBS with BrdU added to the drinking water and continued for five days as shown (C). A group of immunized mice were included that were not given BrdU or sPE (C). At the indicated day after rechallenge,
the percentage of PE-BMEM incorporating BrdU was measured by FACS (C). In parallel, IgG+ PE-PCs were quantified in sPE- and PBS-injected mice from
both the spleen and BM by ELISpot (D). The levels of IgG+ PE-specific serum antibody titers present on the indicated days after sPE injection were compared with titers present in PBS injected mice by ELISA (E). The expression levels of intracellular Ki-67 by PE-BMEM (DumpB220+PE+; pregates not shown;
Dump, CD4+CD8+IgD+IgM+) was measured at the indicated time points after sPE injection by FACS, with representative plots depicted (F). Plots were
stained and analyzed on the same day. To examine the impact of varying sPE dose during rechallenge, PE-immunized mice were rechallenged with 1, 10,
100 µg sPE or PBS only, with BrdU given daily in the drinking water. After 3 d, the percentage of PE-BMEM incorporating BrdU was measured by FACS (G).
The same experimental setup used in G was used in H, except mice were injected with PBS, 1 µg sPE, or 1 µg PE with 50 µg CpG, with BrdU incorporation
by PE-BMEM again depicted. Three to five mice per experimental group were used per experiment. Data presented are representative of two to three independent experiments, with A and B pooled from two independent experiments. Error bars in C–E are expressed as the mean ± SEM. AU, arbitrary units.
2018
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with these BMEM expressing a GL7PNAKi-67hiCD38+
phenotype.
To investigate whether antigen-activated BMEM generate
GCs, GC structures were quantified in spleens where PEBMEM were either unchallenged or were responding to sPE or
sPE + CpG by immunofluorescence (IF) microscopy. As a
positive control for the presence of GCs, naive BALB/c were
immunized with PE/alum and spleens were examined 10 d
later at the height of the GC response. To ensure that PEBMEM in the sPE- and sPE + CpG–treated groups and the
PE-GC B cells in the D10 PE/alum immunized groups were
present and proliferating in these mice, FACS analysis was
performed on half of the spleens, with BrdU incorporation
by B220+PE+ cells analyzed (Fig. S4). Upon IF evaluation, in
the D10 PE/alum immunized spleens, GL7+ clusters were
observed and proximal to CD35+ follicular DCs, with these
structures detected in 50% of the B cell follicles (Fig. 3, C
and D). These GL7+ cell clusters were minimally present in
the PBS-, sPE-, and sPE + CpG–treated groups (Fig. 3, C
and D). Importantly, there was no significant increase in the
number of GCs present in spleens where BMEM were activated by sPE or sPE + CpG in comparison to PBS controls
(Fig. 3 D). These data, coupled with the GL7PNAKi67hiCD38+ phenotype displayed by BMEM after in vivo antigen-dependent activation, demonstrate that GCs are not
created by BMEM after antigen rechallenge.
Analysis of the in vivo BMEM cell response to TLR agonists,
CD40 agonists, and bystander T cell help
The in vivo BMEM response to TLR agonists, CD40 agonists,
and bystander T cell help was determined. PE-immunized
mice were injected with PBS, sPE as a positive control, combinations of TLR agonists, agonistic CD40, and/or CD3.
We treated mice with agonist doses at or greater than doses
known to have an optimal biological effect in vivo (Ferran
et al., 1990; Ahonen et al., 2004). In data where 50 µg of CpG
was used, similar data were obtained using 100 µg (unpublished data). Furthermore, the efficacy of the TLR agonists
was confirmed by observing an induction in the expression of
CD86 by both NF B cells and CD11c+ DCs 24 h after TLR
agonist injection in vivo (unpublished data). PE-BMEM proliferation was tracked by BrdU incorporation over a period of
3 d (Fig. S5 A). NF B cells were included in this analysis and
were identified as B220+IgD+ cells (Fig. S5 B). Injection with
PBS alone elicited very low amounts of BrdU incorporation
by both NF B cells and PE-BMEM, whereas injection with
sPE elicited only BMEM proliferation (Figs. 4, A and B, and
Fig. S5). It was observed that both BMEM and NF B cells proliferate in response to injection with agonistic CD40 antibody alone or coupled with LPS or CpG, with the mean
proliferation of both subsets as measured by BrdU incorporation between 25 and 50% (Fig. 4, A and B, Fig. S5). After in-

jection with LPS, CpG, or CD3 alone or CD3 and LPS or
CpG, no proliferation was observed for either NF B cells or
PE-BMEM (Fig. 4, A and B, and Fig. S5). These data indicate
that both NF B cells and PE-BMEM proliferate in response to
CD40 signals in vivo, whereas TLR agonists or activation
of T cells with CD3 did not induce BMEM proliferation.
To determine whether BMEM differentiate into ASCs after
signaling through CD40, PE-immunized mice were injected
with PBS, sPE, CpG, CD40, or both CD40 and CpG.
IgG+ PE-ASCs after agonist injection were quantified, and
only in the sPE challenged mice was an increase in IgG+ PEASC numbers observed (unpublished data). The numbers of
BM IgG+ PE-ASCs after agonist treatment were also analyzed, with serum harvested on the day of agonist injection
and again when analyzed 14 d later. The only treatment
group in which an increase in numbers of BM IgG+ PEASCs and serum PE-specific IgG was observed in the sPEtreated cohort (Fig. 4, C and D).
These data indicate that TLR4 and TLR9 agonists and
the proinflammatory cytokine storm elicited by agonistic
CD3 treatment are incapable of activating BMEM and driving their proliferation or differentiation in vivo. Engagement
of CD40 (either alone or coupled with TLR4 and TLR9 agonists) drives both NF B cell and BMEM proliferation, but is
incapable of mediating their differentiation into ASCs.
BMEM cells do not proliferate or differentiate into ASCs
in vivo after immunization with an irrelevant protein
antigen or vaccinia virus infection
The capacity of PE-BMEM to proliferate and differentiate in
response to either immunization with NP-KLH/alum administered with CpG or infection with vaccinia virus Western Reserve strain (VACVWR) was analyzed. The levels of
BMEM proliferation and their differentiation into ASCs were
measured 17 d later with this time chosen to allow for the full
development of an adaptive immune response against either
NP-KLH or VACVWR. After immunization with VACVWR
or NP-KLH, PE-BMEM did not incorporate any more BrdU
(15.9% ± SEM 1.8 and 16.6% ± SEM 2.3, respectively) and
then after injection with PBS alone (19.22% ± SEM 1.5; Fig.
S6 C and Fig. 5 A). As anticipated, sPE induced robust PEBMEM cell proliferation, with the majority (73% ± SEM 2.8)
of cells BrdU+ (Fig. S6 C and Fig. 5 A). The generation of
IgG+ PE-ASCs was also measured by comparing the levels of
PE+ IgG+ serum antibody titers present before and after immunization and by quantifying the number of IgG+ PE-ASCs
present in the spleen and BM by ELISPOT. VACVWR and
NP-KLH immunizations did not impact the number of IgG+
PE-ASCs present in either the spleen or the BM 17 d after
immunization (Fig. 5, B and C). There was also no difference
in the levels of IgG+ PE-specific serum antibody titers after
VACVWR or NP-KLH immunization (Fig. 5 D). Consistent

Each point in A, B, G, and H represents an individual mouse, with horizontal line representing the mean. Results of a Student’s t test are shown as comparisons between the indicated experimental groups: ns, no significance; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 3. BMEM cells proliferate upon in vivo antigen encounter and do not express GC markers or generate GC structures. PE-immunized
mice were injected with PBS, 10 µg sPE, or 10 µg sPE + 50 µg CpG. 3 d later, PE-BMEM (Dump-B220+PE+; pregates not shown and Dump =
CD4+CD8+IgD+IgM+) in each treatment group were analyzed for their expression of GL7, PNA, Ki-67, and CD38 by FACS. Included in this analysis were
lymphocytes harvested from the Peyer’s patches of the same mice and gated on B220+IgD (PP-GC; pregates not depicted). Representative data depicted
are histograms of indicated phenotypic marker (A). A similar experiment was performed with responding PE-BMEM examined at various time points after
10 µg sPE rechallenge (B). To detect the presence of GCs in mice harboring antigen-responding BMEM, PE-immunized mice were rechallenged with PBS,
sPE, or sPE + CpG. Included in the analysis were BALB/c mice that had received a primary PE/alum immunization 10 d prior. GCs in each group were quantified by IF microscopy (C) and are represented as the percentage of splenic IgD+ B cell follicles harboring GL7+ foci, with 50–75 follicles counted/spleen
(D). A and B are representative of three experiments, with three to four mice analyzed on each day. The IF experiment contained three mice analyzed from
two independent experiments (C and D). For IF images, green represents GL7, blue represents IgD, and purple represents CD35. Bar, 100 µm. In D, each
point represents an independent mouse, with line representing the mean. Results of an unpaired Student’s t test in D are shown as a comparison between
indicated groups. ***, P < 0.001.
2020
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with our earlier observations (Fig. 2, D and E), sPE induced
a substantial and significant increase in the number of IgG+
PE-ASCs in both the spleen and BM (Fig. 5, B and C) and
led to an 30-fold increase in the levels of IgG+ PE-specific
serum antibody titers (Fig. 5 D). Both cellular and humoral
anti-VACVWR immune responses were verified to have occurred by testing for the presence of IFN-+ VACVWRspecific CD4 and CD8 T cells in spleens harvested from
VACVWR-infected mice, but not naive mice, and by observing for the presence of anti-VACVWR IgG serum antibodies
only in infected mice (Fig. S6, A and B).

Figure 4. Analysis of the in vivo BMEM cell response to TLR agonists, CD40 agonists, and bystander T cell help. PE-immunized mice
were injected i.p. with PBS, 10 µg sPE, 50 µg CpG, 50 µg LPS, 100 µg
CD40, or 5 µg CD3 either alone or in combination as indicated. For A
and B, BrdU was added to the drinking water at the time of injection and
for the duration of the experiment. The percentage of splenic NF B cells
and PE-BMEM incorporating BrdU was analyzed 3 d later by FACS
(A and B, as indicated). To analyze whether CpG and CD40 either alone
or in combination enhanced the number of PE-PCs in the BM, mice received the indicated agonist and were sacrificed 14 d later, with the number of IgG+ PE-PCs in the BM quantified by ELISpot (C). Furthermore,
serum was harvested on the same day as agonist injection (Day 0), as well
as on the day of sacrifice (Day 14), with the titers of IgG+ PE-specific antibody titers analyzed on both days by ELISA (D). In A–C, three to four mice
per experimental group were used per experiment. Data shown is pooled
from three independent experiments. In A–C, each dot depicts an individual mouse, with mean indicated by horizontal line. In D, each group
contains seven mice, with data expressed as the mean ± SEM. AU, arbitrary units. D is the pooled data of two independent experiments. Results
of an unpaired Student’s t test are shown as comparisons between the
indicated experimental group and the PBS control group: no denotation,
no significance. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
JEM VOL. 206, August 31, 2009

These data collectively demonstrate that immunization
with NP-KLH and VACVWR infection does not induce PEBMEM proliferation or differentiation into ASCs. Thus, BMEM
are unresponsive to stimuli generated during a bystander immune response.
DISCUSSION
A detailed analysis of the in vivo secondary immune response
of BMEM in response to cognate antigen versus noncognate
inflammatory bystander signals is presented. These data show
that BMEM respond robustly upon rechallenge with cognate
antigen, but do not acquire the expression of GC markers or
form GCs in response to cognate antigen. In striking contrast,
the response of BMEM to a battery of proinflammatory signals
is remarkably silent. It has been proposed that serological

Figure 5. BMEM cells do not proliferate or differentiate into PCs in
vivo after immunization with an irrelevant protein antigen or vaccinia virus infection. PE-immunized mice were injected i.p. with PBS,
10 µg sPE, 2 × 106 PFU VACVWR, or 100 µg NP-KLH/alum + 50 µg CpG, as
indicated. BrdU was added to the drinking water at the time of injection
and for the duration of the experiment. After 17 d, the percentage of PEBMEM–incorporating BrdU was quantified by FACS analysis (A). On the
same day, the numbers of IgG+ PE-PCs were quantified in both the spleen
and BM for each treatment group by ELISpot (B and C, respectively).
Serum was harvested 3 d before immunization and again on day 17, with
IgG+ PE-specific serum antibody titers from both time points shown
(D). Horizontal lines represent the mean (A–C). In A–C, three to four mice
per experimental group were used per experiment. Data shown in 5A is
pooled from two independent experiments, and data shown in B and C is
representative of one of these experiments. Results in D are expressed as
the mean ± SEM. AU, arbitrary units. Seven to eight mice were used in
each treatment group. D is the pooled data of two independent experiments. Results of an unpaired Student’s t test are shown as comparisons
between the indicated experimental groups in A–C. ***, P < 0.001.
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memory is sustained by BMEM responding to bystander inflammatory signals by undergoing proliferation and differentiation. However, the findings of this study indicate that BMEM
ignore these signals (TLR agonists, polyclonal T cell activation, aggressive vaccination, and acute viral infection), as they
fail to drive BMEM proliferation or differentiation in vivo.
Despite the preponderance of studies detailing the B cell
dynamics of the primary humoral immune response, surprisingly few studies have detailed the events of the secondary
humoral immune response. We have tracked BMEM and demonstrate that cognate antigen drives the rapid clonal expansion of BMEM and their terminal differentiation into ASCs,
with these events occurring in the absence of GC formation.
As has been widely reported, BMEM rapidly differentiate to
ASCs upon secondary antigen encounter (Höfer et al., 2006;
Minges Wols et al., 2007), with this ASC response first detectable 3 d after antigen challenge in both the spleen and the
BM and with the splenic ASC response an order of magnitude greater than that observed in the BM. This wave of
ASCs dissipates after 11 d, and it is probable that the remaining ASCs in the BM 24 d after antigen challenge have been
culled into the long-lived PC pool (Manz et al., 1997; Höfer
et al., 2006; Minges Wols et al., 2007). These data detail the
activation of BMEM and define their proliferation as occurring
between days 2 and 5 after antigen encounter. Proliferating
BMEM occupy a transitional state defined as antigen-binding
B220+CD38+Ki-67+GL7PNA before generating quiescent daughter BMEM and/or differentiating into ASCs. This
blasting state is unique because of the presence of high levels
of CD38 expression by proliferating cells; CD38 is a phenotypic marker previously used to denote quiescent NF B cells
and BMEM and is lost upon B cell activation and entry into the
GC (Oliver et al., 1997). Our finding that BMEM cells do not
form or enter a GC reaction during their differentiation and
expansion is consistent with classical studies indicating that
BMEM might not undergo further SHM and isotype switching
upon rechallenge with antigen (Askonas et al., 1970; Okumura
et al., 1976; Siekevitz et al., 1987). In these studies, limiting
numbers of hapten-specific “parental” BMEM were adoptively
transferred together with carrier-primed T cells into lightly
irradiated hosts, followed by immunization of the hosts
with soluble hapten-carrier antigen. Upon analyzing the
isotype distribution and SHM exhibited by the parental
BMEM and their progeny generated in response to cognate
antigen, no change in diversity in either measure was observed. Our data showing that BMEM neither gain GC markers nor seed GCs are in concordance with these studies. It
is apparent that BMEM, at least in these studies and in our
presented data, are not instructed to enhance the affinity or
isotype distribution of their antigen receptors during secondary antigen encounter.
Our data indicate that quiescent IgG+ BMEM are not activated by TLR agonists or bystander T cell help, and thus do
not undergo self-renewal events or differentiate into ASCs in
an antigen-independent manner. We should note that our
analysis was limited to IgG+ PE-BMEM and that our experi2022

mental system excluded testing whether IgM+ BMEM are responsive to bystander inflammatory signals. There is a growing
body of evidence both in favor of and in conflict with the
hypothesis that serological memory is sustained by the activation of BMEM by bystander inflammation. Evidence in favor
of this theory includes in vitro observations in which human
BMEM were shown to have increased sensitivity and to selectively proliferate and differentiate into ASCs in response to
bystander stimuli as compared with NF B cells (Bernasconi
et al., 2002, 2003). In vivo studies in humans found that for
single-pathogen specificities, serum antibody levels linearly
correlated with the frequency of BMEM present in a host, indicating that the ASC compartment was genealogically linked
to and undergoing replenishment by the BMEM compartment
(Bernasconi et al., 2002). Mouse studies also supported this
link between the BMEM and ASC compartments as elimination of virus-specific BMEM led to a slow decay of virusspecific ASC numbers over time in comparison to mice still
containing BMEM (Slifka et al., 1998). Lastly, it was observed
that during an immune response against a single pathogen, an
increase in both blood ASC numbers and serum antibody
levels occurred for specificities to other pathogens (Bernasconi
et al., 2002). This result was interpreted as evidence that host
BMEM were recipients of antigen-independent stimuli and responded by differentiating into ASCs.
Despite these data suggesting that BMEM respond to bystander inflammation, more recent studies have put this hypothesis under scrutiny. In particular, further attempts to
correlate antigen-specific BMEM numbers with circulating ASCs
in human subjects have been unsuccessful (Amanna et al.,
2007). Mouse studies where long-lived ASC numbers were
quantified after BMEM depletion observed no decay in ASC
numbers over time, contrary to initial reports (Ahuja et al.,
2008; DiLillo et al., 2008). Lastly, a series of studies reported
that in mice that were administered a TLR agonist or in humans that were given a vaccine, ASC numbers and serum antibody levels against specificities other than the immunizing
antigen did not increase (Di Genova et al., 2006; Amanna
et al., 2007; Xiang et al., 2007; Richard et al., 2008).
Our studies show that the in vitro sensitivities of BMEM to
activation are not representative of their sensitivities in vivo
and cast doubt on the hypothesis that BMEM can be activated
by bystander inflammation. Our in vitro studies examining
the response profiles of murine BMEM to both antigen-dependent and -independent stimuli extended prior studies using
human (Arpin et al., 1997; Bernasconi et al., 2002) and murine (Richard et al., 2008) BMEM, as we observe that murine
BMEM are sensitive to TLR agonists and have an enhanced
intrinsic ability to differentiate into ASCs upon activation
with TLR agonists, regardless of whether the BCR is engaged by antigen. Given these data, and our knowledge of
the robust response of BMEM to cognate antigen in vivo, an
exploration of the response of BMEM to several nonspecific
inflammatory signals in vivo demonstrated that BMEM are in
fact unresponsive to these stimuli. The first panel of signals
tested was derived from activated T cells and included CD154
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expression by these cells, as well as proinflammatory cytokines either alone or together with TLR agonists. We first
analyzed the impact of agonistic CD40 antibodies on BMEM
proliferation and differentiation. The injection of mice with
CD40 alone or with TLR4 or TLR9 agonists elicited substantial levels of BMEM and NF B cell proliferation. Despite
this proliferation, these BMEM did not differentiate into ASCs.
These data are in agreement with our in vitro observations,
where CD40 induced the proliferation of, yet failed to differentiate, poly-BMEM into ASCs. These studies also extend
previous in vitro studies where CD40 signaling triggered human BMEM proliferation, but impeded their differentiation
into ASCs (Arpin et al., 1995). Using a second approach, we
activated T cells in vivo through the injection of agonistic
CD3 antibodies, with this treatment given either alone
or with TLR agonists. Injection of this antibody is known
to elicit rapid and transient activation of T cells, which release a proinflammatory cytokine storm that includes IL-2,
IFN-, and TNF (Ferran et al., 1990; Scott et al., 1990).
These stimuli did not induce either BMEM proliferation
or differentiation.
It is highly likely that the in vivo response of BMEM to
overt antibody-mediated CD40 signaling does not represent
the hypothetical situation where BMEM and activated T cells
transiently engage in a CD40/CD40L synapse independent
of an antigen bridge. As we found no BMEM proliferation
upon vaccination with an irrelevant thymus-dependent antigen or infection with vaccinia virus (a situation generating
large numbers of activated CD4 T cells expression CD40L),
it is probable that this interaction does not occur and is thus
not a mechanism for propagating BMEM renewal. Instead, this
data should be interpreted as in vivo proof that CD40 signaling drives BMEM proliferation but blocks their differentiation
into ASCs, indicating that differentiation occurs upon cessation of CD40 signaling.
Immunization with NP-KLH, along with alum and CpG,
and infection with vaccinia virus results in the acute induction
of both innate and adaptive immunity. BMEM ignored the
stimuli associated with these responses and neither proliferated
nor differentiated into ASCs during the multi-week period in
which these immune responses were occurring. In summary,
inflammatory signals associated with TLR signaling, T cell activation, and adaptive immune responses are incapable of driving BMEM proliferation or differentiation into ASCs.
The possibility remains that BMEM and long-lived PCs
might survive for the lifetime of the host, with these populations not requiring self-renewal or replenishment and with
serological memory not requiring maintenance. However,
this hypothesis requires that BMEM and PCs survive for perpetuity, and this quality appears unrealistic. From our presented
work, we show that BMEM do not clonally expand or differentiate in response to bystander inflammatory signals. It is
possible that there are other signals capable of inducing in
vivo BMEM expansion and differentiation that are not included
in this analysis. Alternatively, the maintenance of serological
memory may occur via a stochastic rather than an induced
JEM VOL. 206, August 31, 2009

process, with BMEM not requiring an extrinsic signal to maintain serological memory such as those tested herein.

MATERIALS AND METHODS
Mice and immunizations. These studies were approved by the Institutional Animal Care and Use Committee of Dartmouth College (Lebanon,
NH). BALB/c mice were purchased from the National Cancer Institute.
RAG/ mice were purchased from The Jackson Laboratory. C1-cre mice
crossed with Rosa26-EYFP mice have been previously described and were
provided by K. Rajewsky (Harvard Medical School, Boston MA) and
S. Casola (Fondazione Italiana per la Ricerca sul Cancro Institute of Molecular
Oncology Foundation, Milan, Italy; Casola et al., 2006). All animals were
maintained in a pathogen-free facility at Dartmouth Medical School. For
primary immunizations, 10 µg of R-PE (Cyanotech) or 100 µg of NP28KLH (Biosearch Technologies) adsorbed to prepared alum was injected i.p.
in a volume of 200 µl. For secondary challenge, 10 µg of PE (unless indicated
otherwise) in PBS in a volume of 200 µl was injected i.p. For VACVWR infections, virus was propagated and titered on the 143B cell line as previously
described (Fuse et al., 2008), with 2 × 106 PFU injected i.p. For BrdU treatment, 0.8 mg/ml was added to the drinking water and changed daily except
in Fig. 5 where BrdU was changed every other day.
Cell preparation. Single-cell suspensions of lymphocytes were prepared as
previously described (Benson et al., 2008). For enrichment of splenocytes
for BMEM before phenotyping and BrdU analysis, CD4+, CD8+, IgD+, and
IgM+ cells were removed by negative depletion using a mix of biotinylated
antibodies. Cells were removed using the EasySep Biotin Selection Kit for
Mouse Cells (StemCell Technologies). For enrichment of BMEM before cell
sorting, IgD+ and IgM+ cells were first removed, and then CD43+ cells
were removed in a two-step process using the EasySep Mouse B Cell Enrichment Kit.
Cell culture/reagents. B cells were cultured in RPMI media supplemented with 10% FBS (Atlanta Biologicals), Hepes, 50 µM -ME, and penicillin/streptomycin/l-Glutamine. Sorted B cells were cultured in 96-well
round-bottomed plates with 10,000–15,000 cells/well and were cultured at
37°C. For in vitro VACVWR CD4 and CD8 recall, BALB/c splenocytes
were infected for 2 h with a 10:1 ratio of virus to cells. Infected cells were
then plated in a round-bottom 96-well plate with 5 × 106 splenocytes harvested from either D17 VACVWR-infected or noninfected mice added and
cultured for 6 h in the presence of 10 µg brefeldin-A and 10 U/ml IL-2. Intracellular staining of IFN- was performed as previously described (Fuse
et al., 2008). The following reagents and vendors were used in this study:
CpG-ODN1826 (5-TCCATGACGTTCCTGACGTT-3) with phosphorothioate bases (Eurogentec S.A.), LPS 055:B5, BrdU (Sigma-Aldrich),
Pam4CSK4, HKLM, poly(I:C), ST-FLA, and FSL1 (Invivogen), S-27609
(3M Pharmaceuticals), IL-4 (Peprotech), CD40 clone FGK45, and CD3
clone 145 2C11 antibodies (Klaus Lube; BioExpress).
Flow cytometry. Antibodies against the following antigens were used:
B220 (clone 6B2), IgG1 (clone A85-1), IgD clone (11-26c), IgM (clone 11–
41), CD4 (clone GK1.5), CD8 (clone 2.43), IFN- (clone XMG1.2), CD43
(clone 1B11), CD38 (clone 90), CD23 (clone B3B4), CD80 (clone 1610A1), Ki-67 (clone B56), CD138 (clone 281–2), BrdU (clone PRB-1), CD35
(clone 8C12), GL7, and PNA. NIP-PE and PE-binding cells were detected
by staining with NIP20-PE (generated in-house) or with 2 µg/ml PE. For
CFSE or DDAO dye dilution, cells were labeled with 5 µM CFSE or 10 µM
DDAO in RPMI at 37°C for 10 min (Invitrogen). Intracellular BrdU (BD)
and Ki-67 (eBioscience) staining was performed according to the manufacturers recommendations. Flow cytometry was performed on a refurbished
FACSCAN running CellQuest software (BD), with data analysis performed
using FlowJo (Tree Star, Inc.). Cell sorts were performed on a FACSAria
(BD; Flow Cytometry Facility at Dartmouth Medical School).
2023

ELISpot/ELISA analysis. For ELISpot analysis, cells were apportioned to
PE, NP3-BSA, or polyclonal anti-Ig–coated Multiscreen 96-well plates
(Millipore) with twofold serial dilutions made before incubation for 7–18 h
at 37°C. PCs were detected by HRP-conjugated or biotinylated anti–mouse
IgM, IgG1, IgG2a, IgG2b, IgG3, IgE, or IgA polyclonal antibodies (SouthernBiotech.), with streptavidin-HRP used in a second step when necessary.
ELISpots were developed as previously described (Benson et al., 2008).
For ELISA analysis, plates were coated with either 10 µg/ml PE or 4 × 106
PFU of H2O2-inactivated VACVWR (Hammarlund et al., 2008) overnight in
PBS, blocked with PBS + 5% FBS, and washed, and then 1:2,000 diluted
serum added at serial 1:2 dilutions. Serum from either a PE hyperimmunized
mouse or from a VACVWR mouse was included on each plate as a reference
between plates and between experiments and used to generate a standard
curve, with these serum allotted the value 8,000 arbitrary units. Antibody
levels were detected with IgG-AP (SouthernBiotech) and developed with
1 mg/ml pNPP (Sigma-Aldrich) in 0.05 sodium carbonate buffer.
Immunofluoresence microscopy. Spleens were presoaked in 15%
sucrose/PBS for 30 min and snap-frozen in OCT compound (Sakura Finetek)
in a dry ice/ethanol slurry and stored at 80°C. Tissues were sectioned onto
slides using a cryostat with 8-µm-thick sections. After drying at room temperature, the tissue was fixed in ice-cold 1:1 acetone/methanol mix for 10 min
and allowed to dry, after which sections were outlined with an ImmEdge
Pen (Vector Laboratories). Sections were blocked with 10% heat-inactivated
normal rat serum/PBS for 1 h, washed, and stained with IgD-Alexa Fluor
647, GL7-FITC, and CD35-biotin, followed by staining with SA-PerCP.
After washing, slides were mounted with PermaFluor Aqueous Mounting
Media (Thermo Fisher Scientific). Samples were analyzed on a LSM 510
META confocal microscope using LSM software (Carl Zeiss, Inc.).
Online supplemental material. Fig. S1 shows FACS gating scheme
and phenotype of PE-BMEM. Fig. S2 displays the FACS profiles and gating schemes used to sort-purify PE-BMEM, NP-BMEM, and NF B cells.
Fig. S3 contains FACS profiles showing BrdU incorporation by PE-BMEM
and data corresponding to experiments presented in Fig. 2. Fig. S4 contains FACS plots showing BrdU incorporation by PE-BMEM and D10 GC
B cells, with these data corresponding to experiments presented in Fig. 3.
Fig. S5 contains FACS plots showing BrdU incorporation by PE-BMEM and
NF B cells after in vivo administration of TLR agonists, CD40 agonists,
and bystander T cell help. Data correspond to experiments presented in Fig.
4. Fig. S6 depicts the presence of VACVWR-specific CD4 and CD8 cells
and VACVWR–specific serum IgG in infected hosts. FACS plots are also
depicted showing levels of BrdU incorporation by PE-BMEM after protein
vaccination or viral infection, with data corresponding to experiments depicted in Fig. 5. Online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20090667/DC1.
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